Pascal Soriot


Despite bullying by Brussels, Pascal Soriot is turning AstraZeneca into a global powerhouse

A convoluted boardroom reshuffle at the top of AstraZeneca is likely to revive scrutiny of its highly ambitious £30bn swoop on US biotech firm Alexion. Marc Dunoyer, AstraZeneca’s finance chief of seven years, is stepping down to be replaced by his American counterpart Aradhana Sarin, but Dunoyer will stay on to become chief Astra’s chief strategy officer, as well as the new boss of Alexion, which will become the fulcrum of the company's rare disease arm.
Medical & BiotechMedicalXpress

AstraZeneca's Pascal Soriot: the man behind the vaccine

Pascal Soriot has led the charge to make AstraZeneca one of the first pharmaceutical companies in the world to produce a vaccine against COVID-19. The development of the vaccine with scientists at Oxford University—and their decision to make it available at cost—has made the Anglo-Swedish firm a household name. Since...
Medical &

Pas­cal So­ri­ot cash­es in As­traZeneca’s chips on Mod­er­na for $1.2B cash in­jec­tion

While still working to prove its own Covid-19 vaccine, AstraZeneca has reportedly capitalized on the success of another. The company has sold off its 7.7% stake in Moderna and turned it into $1.2 billion in cash, according to the Times, beefing up the reserves just as Pascal Soriot is wrapping up his $39 billion acquisition of Alexion and its rare disease pipeline.

AstraZeneca CEO Pascal Soriot Took Home $21.4 Million in 2020

AstraZeneca Chief Executive Officer Pascal Soriot is seeing a significant return on the fruits of his company’s labor in 2020. Soriot’s annual compensation jumped a bit from the previous year to $21.4 million. Since his time at the helm of the company, Soriot has overseen significant growth in the company’s...

Pascal Soriot on First Doses First

Pascal Soriot, CEO of AstraZeneca, in an interview:. I think the UK one-dose strategy is absolutely the right way to go, at least for our vaccine. I cannot comment about the Pfizer vaccine, whose studies are for a three-week interval….First of all, we believe that the efficacy of one dose is sufficient: 100 percent protection against severe disease and hospitalisation, and 71-73 percent of efficacy overall.